Exclusive: Ohana, Flagship's big bet on fertility treatments, shuts down and lays off staff after VC pulls the plug
A little over a year after emerging from stealth, Flagship’s grand attempt to remake fertility is shutting down.
Ohana Biosciences CEO Amber Salzman confirmed in an email to Endpoints News that the board — overwhelmingly drawn from Flagship’s ranks — decided on Tuesday to wind down the company after they failed to raise enough cash to keep it going. They are cutting staff to “minimal operations,” she said, while working to find new positions for laid off employees.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.